Arcus Biosciences-Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Arcus Biosciences(US:RCUS) Businesswire·2025-10-13 06:05

临床研究进展 - 公司宣布针对局部晚期不可切除或转移性胃、胃食管结合部或食管腺癌患者的2期EDGE-Gastric研究A1组的首次总生存期结果 [1] - 正在进行的EDGE-Gastric研究是一项多组别、全球性的2期研究 [1] 公司业务聚焦 - 公司为临床阶段全球生物制药公司，专注于为癌症患者开发差异化分子和组合疗法 [1]